相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections
Aubin Souche et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Locally delivered antistaphylococcal lysin exebacase or CF-296 is active inmethicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
Melissa Karau et al.
JOURNAL OF BONE AND JOINT INFECTION (2022)
Exebacase in Addition to Daptomycin against MRSA
Razieh Kebriaei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection
Steven M. Swift et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus
Aubrey Watson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography
Sonia U. Shah et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis
Vance G. Fowler et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus
Jun Taek Oh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis
Aubrey Watson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats
Melissa J. Karau et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015-2017
Maria Traczewski et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Mechanisms of Immune Evasion and Bone Tissue Colonization That Make Staphylococcus aureus the Primary Pathogen in Osteomyelitis
Gowrishankar Muthukrishnan et al.
CURRENT OSTEOPOROSIS REPORTS (2019)
Evolving concepts in bone infection: redefining biofilm, acute vs. chronic osteomyelitis, the immune proteome and local antibiotic therapy
Elysia A. Masters et al.
BONE RESEARCH (2019)
Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent
Raymond Schuch et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia
Raymond Schuch et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of America
Douglas R. Osmon et al.
CLINICAL INFECTIOUS DISEASES (2013)